Research programme: monoclonal antibody therapeutics - Tetragenetics/argenx /Crystal Bioscience/Sevion Therapeutics

Drug Profile

Research programme: monoclonal antibody therapeutics - Tetragenetics/argenx /Crystal Bioscience/Sevion Therapeutics

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator arGEN-X; Crystal Bioscience; Sevion Therapeutics; Tetragenetics
  • Developer argenx; Crystal Bioscience; Sevion Therapeutics; Tetragenetics
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Ion channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders

Most Recent Events

  • 23 Dec 2015 Tetragenetics, arGEN-X, Crystal Bioscience and Sevion Therapeutics enter into a collaboration agreement to discover and develop monoclonal antibodies for autoimmune disorders in USA .
  • 17 Dec 2015 Early research in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top